Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Noteableon Jan 09, 2024 9:35pm
130 Views
Post# 35818577

RE:Conventional triple negative BC drug long term side effects

RE:Conventional triple negative BC drug long term side effectsIn 2021 Pfizer for the first time talked up its own PD-(L)1 challenger, sasanlimab. 

Pfizer returned the anti-PD-L1 Bavencio to Merck KGaA in 2023, which it originally licensed in 2014. Interestingly, sasanlimab was also included in that 2014 deal: Pfizer says the molecule had been originated in house, but the two companies agreed to work together on it, before Pfizer regained rights in December 2018, according to US SEC filings.


https://www.evaluate.com/vantage/articles/news/corporate-strategy/pfizer-reveals-its-pd-1-secret
<< Previous
Bullboard Posts
Next >>